Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03464656
Other study ID # 16351/16
Secondary ID
Status Recruiting
Phase Phase 4
First received February 26, 2018
Last updated March 7, 2018
Start date January 1, 2018
Est. completion date December 1, 2018

Study information

Verified date January 2018
Source Hamad Medical Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed research aims to study the effects of antioxidant therapy, commonly used in male infertility treatment, on semen analysis. Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study. They will be asked to provide a sample of semen for routine semen analysis and advanced semen tests including sperm DNA fragmentation and sORP before starting with antioxidant therapy and after 3-month treatment with antioxidants.

After completing the data analysis, we intend to publish the study in high impact perr reviewed journals and present it in international conferences.


Description:

The proposed research aims to study the effects of antioxidant therapy, commonly used in male infertility treatment, on semen analysis. Several studies have been conducted to evaluate the effect of many antioxidant regimens on male infertility. A randomized double-blind, placebo-controlled trial investigated a combined antioxidant regimen, including vitamin C, using Menevit (lycopene 6mg, vitamin E 400IU, vitamin C 100mg, zinc 25mg, selenium 26 mcg, folate 0.5mg, garlic 1g) in couples undergoing intracytoplasmic sperm injection. The authors reported a significant improvement in viable pregnancy rate in the treatment group, where 38.5% of transferred embryos resulted in a viable fetus compared to 16% in the placebo group (Tremellen K, 2007). Suleiman et al. studied 300 mg of daily vitamin E in a placebo-controlled study revealing significant improvement in sperm motility and reduction of oxidative stress measures in the treatment group. Moreover, they reported a 21% spontaneous pregnancy rate in the treatment group compared to 0% in the placebo group (Suleiman SA, 1996).

Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study. They will be asked to provide a sample of semen for routine semen analysis and advanced semen tests including sperm DNA fragmentation and sORP before starting with antioxidant therapy and after 3-month treatment with antioxidants. No other procedures will be done for research purposes. All other investigations or treatments will be given according to the standard of care. Routinely patients presenting to the male infertility unit at HMC seeking evaluation and treatment for delayed conception will be assessed with a history and physical examination, investigated with semen and endocrine studies and be placed on an antioxidant regimen comprised of vitamins C and E, L-Carnitine and pentoxyfylline. Further management will be individualized and planned according to each patient's condition.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2018
Est. primary completion date July 1, 2018
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:

- Abnormal sperm parameters defined as having at least two out of the following three criteria:

- Sperm Concentration > 1 and = 15 million per ml

- Sperm total Motility = 40%

- Sperm Morphology by Strict Criteria; normal forms = 4.0%

- Absence of infection in semen (pus cells < 1 X 106/ml)

- No history of taking any therapy for their infertility including OTC treatment and vitamin supplementation

- No history of obstructive azoospermia

- No history of testicular cancer

Exclusion Criteria:

- Semen volume = 1.5 mL

- Hydrocele, clinical varicocele (grade 2 and higher), orchitis, epididymitis, Cryptorchidism, irradiation or subjects that received chemotherapy treatment

- Clinically meaningful endocrinopathy defined as an endocrinopathy which requires endocrine medications (e.g. Diabetes, Thyroid disease, Pituitary diseases, Adrenal diseases, etc.) or measurement of the following hormonal values:

1. Testosterone < 10.4 nmol/L

2. LH <1 or > 9 IU/L and or FSH <1 or >19 IU/mL

3. Elevated prolactin >407 mIU/L

4. Elevated TSH > 4.5 U/mL

5. Elevated Estrogen> 275 pmol/L

- Leukocytospermia: WBC count of > 1 X 106/ ml

- Known HIV infection

- Use of antioxidant agents or vitamins within 8 weeks prior to inclusion into the study

- Consumption of more than 1 unit of alcohol daily*

- Subjects following any special diet including, but not limited to liquid, high or low protein, raw food, vegetarian or vegan, etc.

- History of current use of illegal or "recreational" drugs

- History of malignancy not curatively treated at least 5 years before screening visit with exception of basal cell carcinoma in situ which may have been curatively treated within 1 year

- Participation in another clinical trial within 30 days or 7 half-lives of the prior test product, whichever is longer

- Any condition which, in the opinion of the investigator, might put the subject at risk by participation in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fairhaven Pro for men
Fairhaven Pro for men The antioxidant formula (Fairhaven Health) contains: B12 (1000 mcg) Zinc (30 mg) Selenium (140 mcg) Arginine (350 mg) L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine CoQ10 (200 mg) Vitamin C (120 mg) and Vitamin E (200 IU)
Diagnostic Test:
Semen analysis
Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment. After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010).
Sperm DNA fragmentation
Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
Static Oxidation reduction potential in semen
Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.

Locations

Country Name City State
Qatar Hamad Medical Corporation Doha

Sponsors (2)

Lead Sponsor Collaborator
Hamad Medical Corporation Fairhaven Health

Country where clinical trial is conducted

Qatar, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the effect of antioxidant therapy on sperm motility in infertile men, Measured by mean change in sperm motility pre- and post-treatment with antioxidants. 1 year
Primary Evaluate the effect of antioxidant therapy on sperm morphology in infertile men Measured by the mean change in sperm morphology pre- and post-treatment with antioxidants 1 year
Primary Evaluate the effect of antioxidant therapy on sperm count in infertile men Measured by mean change in sperm count pre- and post-treatment with antioxidants. 1 year
Secondary Evaluate the effect of antioxidant therapy on sperm DNA fragmentation in infertile men Difference in mean change in sperm DNA fragmentation pre and post-treatment 1 year
Secondary Evaluate the effect of antioxidant therapy on oxidative stress in infertile men Measure difference in mean change in seminal oxidation reduction potential in infertile men pre- and post-treatment. 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Recruiting NCT04955782 - Abstinence Period and Semen Quality
Recruiting NCT05506722 - Using of Testes Shocker in Improving the Spermatogenesis and Sperms Activity N/A
Not yet recruiting NCT03988361 - Selection of Non Apoptotic Human Sperm for in Vitro Fertilization by Using Magnetic Activated Cell Sorting (MACS)
Completed NCT03319654 - Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle N/A
Not yet recruiting NCT05597631 - G-IVF and Sperm Parameters N/A
Completed NCT05919186 - Effects of Antioxidant Supplementation of Culture Media on IVF Embryos N/A
Recruiting NCT03588949 - Role of Nutritional Support in Idiopathic Male Infertility N/A
Recruiting NCT03527043 - Impact of Escitalopram on Sperm DNA Fragmentation Phase 2
Completed NCT02932865 - Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility
Completed NCT02310087 - Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures N/A
Completed NCT00385346 - Expressive Writing in Male Infertility N/A
Completed NCT04509583 - The Role of Micro Nutrient Supplement in Improvement of the Sperm DNA Fragmentation N/A
Recruiting NCT04144244 - Comparison of the Effect of Microchip and Density Gradient Methods in Intrauterine Insemination Cycles N/A
Recruiting NCT04452305 - Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting N/A
Completed NCT05461079 - Sperm Phenotype and Differentially Methylated Regions
Recruiting NCT05205733 - Expanding Fertility Care to Poor and Low Resourced Settings Study N/A
Completed NCT03960229 - The Evaluation of the Effect of Microfluidic Sperm Sorting Chip 'Labs-on-a-chip' on IVF Success in Male Factor N/A
Not yet recruiting NCT06050031 - Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility
Not yet recruiting NCT03090438 - IVF Outcomes After Varicocele Repair N/A